In non-metastatic bladder cancer patients post-cystectomy, HER2-positive CTCs benefited from targeted therapies, whereas HER2-negative CTCs indicated resistance against immunotherapy [101]. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.